- Home
- RRGB vs CUE Comparison
RRGB vs CUE Comparison
Compare RRGB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRGB | CUE |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.5M | 49.6M |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RRGB | CUE |
|---|---|---|
| Price | $4.09 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $9.67 | $3.00 |
| AVG Volume (30 Days) | 182.9K | ★ 1.3M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,226,409,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $0.23 |
| 52 Week High | $7.89 | $1.75 |
Technical Indicators
Market Signals| Indicator | RRGB | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 33.41 |
| Support Level | $3.98 | $0.23 |
| Resistance Level | $4.35 | $0.33 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 21.21 | 27.03 |
Price Performance
Historical ComparisonAbout RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.